PF-Atlas › Clinical Trials › NCT01910415
Phase 1, QT/QTC Interval Study in Healthy Subjects
Lumacaftor · Phase 1
Registry ID
NCT01910415
Phase
Phase 1
Status
Completed
Drug / intervention
Lumacaftor
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2013-06
About this trial
Lumacaftor is evaluated in NCT01910415, a Phase 1 idiopathic pulmonary fibrosis study sponsored by Vertex Pharmaceuticals Incorporated. Current status: Completed.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT01910415 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.